Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHRA reclassifies oral azithromycin as OTC for Chlamydia

This article was originally published in Scrip

Executive Summary

Actavisis to make a generic antibiotic that can treat Chlamydia, azithromycin, available over the counter without a prescription at UK pharmacies later this year, the country's regulator the MHRAsays. It will be the first oral antibiotic to be approved for reclassification and will be marketed under the trade name Clamelle. The pill will be available to patients aged 16 years and over if they have tested positive to the infection and have no symptoms, and for their sexual partners. The Royal Pharmaceutical Society of Great Britainwelcomed the news, pointing out that improving access to Chlamydia treatment would help curb increasing rates of infection, particularly in the under 25s.

You may also be interested in...



Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel